0.06 | 1.96%
PLURISTEM THERAPEUTICS INC's gross profit margin for the second quarter of its fiscal year 2013 has significantly decreased when compared to the same period a year ago. Sales and net income have dropped, although the growth in revenues underperformed the average competitor within the industry, the net income growth did not.
At the same time, stockholders' equity ("net worth") has greatly increased by 71.10% from the same quarter last year.
| Income Statement | Q2 FY13 | Q2 FY12 |
|---|---|---|
| Net Sales ($mil) | 0.2 | 0.23 |
| EBITDA ($mil) | -4.74 | -2.02 |
| EBIT ($mil) | -4.88 | -2.12 |
| Net Income ($mil) | -4.49 | -1.99 |
| Balance Sheet | Q2 FY13 | Q2 FY12 |
|---|---|---|
| Cash & Equiv. ($mil) | 64.57 | 41.52 |
| Total Assets ($mil) | 79.12 | 49.64 |
| Total Debt ($mil) | 0.0 | 0.0 |
| Equity ($mil) | 69.04 | 40.35 |
| Profitability | Q2 FY13 | Q2 FY12 |
|---|---|---|
| Gross Profit Margin | -2429.74 | -872.73 |
| EBITDA Margin | -2429.74 | -872.72 |
| Operating Margin | -2504.62 | -916.88 |
| Sales Turnover | 0.01 | 0.01 |
| Return on Assets | -21.22 | -25.83 |
| Return on Equity | -24.32 | -31.77 |
| Debt | Q2 FY13 | Q2 FY12 |
|---|---|---|
| Current Ratio | 10.82 | 8.81 |
| Debt/Capital | 0.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 |
| Interest Coverage | 0.0 | 0.0 |
| Share Data | Q2 FY13 | Q2 FY12 |
|---|---|---|
| Shares outstanding (mil) | 58.33 | 44.12 |
| Div / share | 0.0 | 0.0 |
| EPS | -0.08 | -0.05 |
| Book value / share | 1.18 | 0.91 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 184762.0 | 249084.0 |
SELL. This stock?s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 2.58 indicates valuation on par with the S&P 500 average of 2.44 and a significant discount versus the industry average of 9.88. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, PLURISTEM THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PSTI NM | Peers 32.50 | PSTI NM | Peers 48.70 | |||||||||||||||||||||
|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. PSTI's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. PSTI's P/CF is negative making the measure meaningless. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| PSTI NM | Peers 31.25 | PSTI NA | Peers 0.70 | |||||||||||||||||||||
|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. PSTI's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| PSTI 2.58 | Peers 9.88 | PSTI -6.25 | Peers 5.98 | |||||||||||||||||||||
|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. PSTI is trading at a significant discount to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, PSTI is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| PSTI 247.97 | Peers 513.82 | PSTI 87.27 | Peers 69.95 | |||||||||||||||||||||
|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. PSTI is trading at a significant discount to its industry on this measurement. |
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share. PSTI has a sales growth rate that exceeds its peers. |
|||||||||||||||||||||||
